Differential relationships between anemia and outcome in subgroups of patients with chronic heart failure

Circulation Journal

Volumn 79, Issue 9, 2015, Pages 1893-1894

  Nakagawa, Yasuaki ^a   Yasuno, Shinji ^b   Kuwahara, Koichiro ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CARDIOVASCULAR MORTALITY; DISEASE ASSOCIATION; EDITORIAL; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; IRON DEFICIENCY; ISCHEMIC HEART DISEASE; QUALITY OF LIFE; TREATMENT OUTCOME; FEMALE; MALE;

ANEMIA; FEMALE; HEART FAILURE; HUMANS; MALE;

EID: 84940026031     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0852     Document Type: Editorial

References (15)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics--2015 update: A report from the American Heart Association. Circulation 2015; 131: e29-e322, doi:10.1161/CIR.0000000000000152.
2. Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52: 818-827.
3. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014; 64: 2281-2293.
4. Yamauchi T, Sakata Y, Takada T, Nochioka K, Miura M, Tadaki S, et al; on behalf of the CHART-2 investigators. Prognostic impact of anemia in patients with chronic heart failure: With special reference to clinical background: Report from the CHART-2 study. Circ J 2015; 79: 1984-1993.
5. Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, et al; CHART-2 Investigators. Usefulness of combined risk stratification with heart rate and systolic blood pressure in the management of chronic heart failure: A report from the CHART-2 study. Circ J 2013; 77: 2954-2962.
6. Nochioka K, Sakata Y, Takahashi J, Miyata S, Miura M, Takada T, et al; CHART-2 Investigators. Prognostic impact of nutritional status in asymptomatic patients with cardiac diseases: A report from the CHART-2 study. Circ J 2013; 77: 2318-2326.
7. Felker GM, Shaw LK, Stough WG, O'Connor CM. Anemia in patients with heart failure and preserved systolic function. Am Heart J 2006; 151: 457-462.
8. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, et al. Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. Circulation 2006; 113: 986-994.
9. von Haehling S, van Veldhuisen DJ, Roughton M, Babalis D, de Boer RA, Coats AJ, et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: Results from the SENIORS study. Eur J Heart Fail 2011; 13: 656-663.
10. Ather S, Chan W, Bozkurt B, Aguilar D, Ramasubbu K, Zachariah AA, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59: 998-1005.
11. Bhatia RS, Tu JV, Lee DS, Austin PC, Fang J, Haouzi A, et al. Outcome of heart failure with preserved ejection fraction in a population- based study. N Engl J Med 2006; 355: 260-269.
12. Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368: 1210-1219.
13. Maurer MS, Teruya S, Chakraborty B, Helmke S, Mancini D. Treating anemia in older adults with heart failure with a preserved ejection fraction with epoetin alfa: Single-blind randomized clinical trial of safety and efficacy. Circ Heart Fail 2013; 6: 254-263.
14. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
15. Filippatos G, Farmakis D, Colet JC, Dickstein K, Luscher TF, Willenheimer R, et al. Intravenous ferric carboxymaltose in irondeficient chronic heart failure patients with and without anaemia: A subanalysis of the FAIR-HF trial. Eur J Heart Fail 2013; 15: 1267-1276.